The need for longer time horizons for cost-utility evaluation in bullous pemphigoid

Br J Dermatol. 2018 Mar;178(3):809-810. doi: 10.1111/bjd.16213. Epub 2018 Feb 7.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Cost-Benefit Analysis
  • Doxycycline
  • Humans
  • Pemphigoid, Bullous*
  • Prednisolone

Substances

  • Prednisolone
  • Doxycycline